Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
Globus Medical Inc (NYSE: GMED) closed the day trading at $55.97 down -5.41% from the previous closing price of $59.17. In other words, the price has decreased by -$5.41 from its previous closing price. On the day, 2.21 million shares were traded. GMED stock price reached its highest trading level at $58.875 during the session, while it also had its lowest trading level at $55.84.
Ratios:
For a better understanding of GMED, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 16.43 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.50. For the most recent quarter (mrq), Quick Ratio is recorded 2.72 and its Current Ratio is at 4.45. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On January 10, 2025, BofA Securities Upgraded its rating to Neutral which previously was Underperform but kept the price unchanged to $97.
Morgan Stanley Upgraded its Equal-Weight to Overweight on December 02, 2024, whereas the target price for the stock was revised from $83 to $100.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 28 ’25 when RHOADS ANN D sold 7,500 shares for $78.68 per share. The transaction valued at 590,100 led to the insider holds 35,384 shares of the business.
RHOADS ANN D bought 7,500 shares of GMED for $590,000 on Feb 28 ’25. On Jan 10 ’25, another insider, Pfeil Keith W, who serves as the COO, CFO of the company, sold 14,167 shares for $88.29 each. As a result, the insider received 1,250,770 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GMED now has a Market Capitalization of 7577163264 and an Enterprise Value of 7621614592. As of this moment, Globus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 41.87, and their Forward P/E ratio for the next fiscal year is 15.28. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.28. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.02 while its Price-to-Book (P/B) ratio in mrq is 1.85. Its current Enterprise Value per Revenue stands at 3.036 whereas that against EBITDA is 10.576.
Stock Price History:
The Beta on a monthly basis for GMED is 1.21, which has changed by -0.18088686 over the last 52 weeks, in comparison to a change of 0.11708844 over the same period for the S&P500. Over the past 52 weeks, GMED has reached a high of $94.93, while it has fallen to a 52-week low of $54.48. The 50-Day Moving Average of the stock is -9.61%, while the 200-Day Moving Average is calculated to be -25.14%.
Shares Statistics:
Over the past 3-months, GMED traded about 1.49M shares per day on average, while over the past 10 days, GMED traded about 1446020 shares per day. A total of 112.93M shares are outstanding, with a floating share count of 112.29M. Insiders hold about 17.06% of the company’s shares, while institutions hold 82.36% stake in the company. Shares short for GMED as of 1749772800 were 4640087 with a Short Ratio of 3.12, compared to 1747267200 on 4509326. Therefore, it implies a Short% of Shares Outstanding of 4640087 and a Short% of Float of 4.6.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
As of right now, 14.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.8, with high estimates of $0.86 and low estimates of $0.74.
Analysts are recommending an EPS of between $3.36 and $3.03 for the fiscal current year, implying an average EPS of $3.16. EPS for the following year is $3.69, with 14.0 analysts recommending between $3.91 and $3.43.
Revenue Estimates
12 analysts predict $738.91M in revenue for the current quarter. It ranges from a high estimate of $763.6M to a low estimate of $717.9M. As of the current estimate, Globus Medical Inc’s year-ago sales were $629.69MFor the next quarter, 12 analysts are estimating revenue of $734.81M. There is a high estimate of $747M for the next quarter, whereas the lowest estimate is $724.1M.
A total of 13 analysts have provided revenue estimates for GMED’s current fiscal year. The highest revenue estimate was $2.9B, while the lowest revenue estimate was $2.79B, resulting in an average revenue estimate of $2.85B. In the same quarter a year ago, actual revenue was $2.52BBased on 13 analysts’ estimates, the company’s revenue will be $3.1B in the next fiscal year. The high estimate is $3.14B and the low estimate is $3B.
